ClinicalTrials.gg
CompletedNCT00804648Updated Mar 6, 2015Results posted

Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Phase 4 interventional study of Timolol Maleate in Sorbate and Timolol hemihydrate in Glaucoma, Open Angle and Ocular Hypertension, sponsored by Vistakon Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2015-03-06.

Sponsored by Vistakon Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing timolol in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. Timolol · Glaucoma, Open-Angle.

Enrollment
23rd of 24
30 · median 77
Started
2008
with 1 other
Phase 4
13 of 24
none open now
Registered
8th of 24
by date

Among the 24 studies testing timolol in Glaucoma, Open-Angle, this one is the 23rd largest by enrollment, is one of 2 that started in 2008, is one of 13 in phase 4, and was the 8th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 24 studies testing timolol in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →

About timolol

Timolol: first FDA approval 1978 (TIMOPTIC), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing timolol in Glaucoma, Open-Angle as a file.
02

Study summary

This study compares patient symptoms and anterior segment safety in patients treated with timolol hemihydrate, generic timolol gel forming solution or timolol maleate.

03

Conditions studied

  • Glaucoma, Open Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • willing to comply with investigator's and protocol's instructions
  • patients signature on the document
  • primary open-angle glaucoma, pigment dispersion or exfoliation glaucoma, or ocular hypertension in at least one eye
  • at screening intraocular pressure must be considered to be safe, in both eyes
  • in non-qualifying eyes the intraocular pressure should be able to be controlled safely on no pharmacologic therapy or on study medicine alone
  • currently treated with one glaucoma medication, untreated intraocular pressure of less than or equal to 28 mm Hg at visit 2 in both eyes

Exclusion criteria

Exclusion Criteria:

  • any abnormality preventing reliable applanation tonometry in either eye
  • any opacity or subject uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber in either eye
  • any concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye
  • any history of allergic or poor tolerance to any components of the preparations used in this trial
  • females of not using reliable means of
  • pregnant or lactating females
  • any , serious, or severe medical or psychiatric condition
  • participation (or current participation) in any drug or device trial within 30 days prior to Visit 1
  • severe prior visual acuity or field loss from any cause
  • inability to understand the trial procedures, and thus inability to give
  • progressive retinal or optic nerve disease apart from glaucoma
  • serious systemic or ocular disease
  • intraocular laser surgery within the past three months or corneal or intraocular conventional surgery within the past 6 months
  • concurrent use of systemic , by IV, oral, dermal or topical ophthalmic route.
  • subjects requiring tear replacement drops or allergy medications with sympathomimetics 24 hours prior to a scheduled study visit
  • to beta-blocker usage including: reactive airway disease, uncontrolled heart failure, or second as well as third degree cardiac block, myasthenia gravis
  • any subject the investigator believes will be at risk for glaucomatous progression by their participation in this trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    hemihydrate/maleate/maleate gel

    Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%

    Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution

  • Active comparator
    maleate/maleate gel/hemihydrate

    Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%

    Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution

  • Active comparator
    maleate gel/hemihydrate/maleate

    Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%

    Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution

  • Active comparator
    hemihydrate/maleate gel/maleate

    Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%

    Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution

  • Active comparator
    maleate/hemihydrate/maleate gel

    Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%

    Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution

  • Active comparator
    maleate gel, maleate, hemihydrate

    Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%

    Drug: Timolol Maleate in Sorbate · Drug: Timolol hemihydrate · Drug: Timolol maleate gel forming solution

Interventions

  • DrugTimolol Maleate in Sorbate

    0.5%

  • 0.5%

  • DrugTimolol maleate gel forming solution

    0.5%

06

What researchers measure

Primary outcomes

  1. Stinging on Instillation

    Assessed from subject response to survey question asking about tolerability of medicine upon instillation, using a 0 through 7 scale, with 0=complete comfort and 7=worst pain imaginable.

    Time frame: following 3 days of treatment

Secondary outcomes

  1. Conjunctival Hyperemia

    Assessed by investigator using a slit lamp and a photographic grading scale. Photographs were graded: grade 0, grade 1, grade 2, grade 3. The higher the graded the worse the hyperemia.

    Time frame: following 3 days of treatment

  2. Tear Film Break-up Time

    Time frame: following 3 days of treatment

  3. Corneal Staining Grade

    Assessed by the investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5. The higher the grade the worse the staining.

    Time frame: following 3 days of treatment

  4. Corneal Staining Count

    Assessed by the investigator using a slit lamp, counting the number of spots.

    Time frame: following 3 days of treatment

  5. Intraoclular Pressure

    Time frame: following 3 days of treatment

  6. Basic Schirmer's

    Schirmer's measures basic tear function. The higher the number, the less dry the eye.

    Time frame: following 3 days of treatment

  7. Conjunctival Staining - Nasal Grade

    Assessed by investigator using a slit lamp and the Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.

    Time frame: following 3 days of treatment

  8. Conjunctival Staining - Nasal Count

    Assessed by investigator using slit lamp and counting number of spots.

    Time frame: following 3 days of treatment

  9. Conjunctival Staining - Temporal Grade

    Assessed by investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.

    Time frame: following 3 days of treatment

  10. Conjunctival Staining - Temporal Count

    Assessed by investigator using a slit lamp and counting number of spots.

    Time frame: following 3 days of treatment

  11. Visual Acuity

    The visual acuity score is a count of the number of letters the subject successfully read from the eye chart. The higher the score, the better the vision.

    Time frame: following 3 days of treatment

07

Results

Posted Oct 20, 2010

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneHemihydrate/Maleate/Maleate GelMaleate/Maleate Gel/HemihydrateMaleate Gel/Hemihydrate/MaleateHemihydrate/Maleate Gel/MaleateMaleate/Hemihydrate/Maleate GelMaleate Gel/Maleate/Hemihydrate
Started356448
Completed356448
Not completed000000
Second Intervention
Participant flow — Second Intervention
MilestoneHemihydrate/Maleate/Maleate GelMaleate/Maleate Gel/HemihydrateMaleate Gel/Hemihydrate/MaleateHemihydrate/Maleate Gel/MaleateMaleate/Hemihydrate/Maleate GelMaleate Gel/Maleate/Hemihydrate
Started356448
Completed356448
Not completed000000
Third Invervention
Participant flow — Third Invervention
MilestoneHemihydrate/Maleate/Maleate GelMaleate/Maleate Gel/HemihydrateMaleate Gel/Hemihydrate/MaleateHemihydrate/Maleate Gel/MaleateMaleate/Hemihydrate/Maleate GelMaleate Gel/Maleate/Hemihydrate
Started356448
Completed356448
Not completed000000

Outcome measures

PrimaryStinging on Instillation

Assessed from subject response to survey question asking about tolerability of medicine upon instillation, using a 0 through 7 scale, with 0=complete comfort and 7=worst pain imaginable.

Time frame:
following 3 days of treatment
Reported as:
Mean · Units on a scale
Stinging on Instillation
Units on a scaleTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Stinging on Instillation0.6 ± 1.01.0 ± 1.40.6 ± 1.0
SecondaryConjunctival Hyperemia

Assessed by investigator using a slit lamp and a photographic grading scale. Photographs were graded: grade 0, grade 1, grade 2, grade 3. The higher the graded the worse the hyperemia.

Time frame:
following 3 days of treatment
Reported as:
Mean · Units on a scale
Conjunctival Hyperemia
Units on a scaleTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Conjunctival Hyperemia0.2 ± 0.50.4 ± 0.50.3 ± 0.5
SecondaryTear Film Break-up Time
Time frame:
following 3 days of treatment
Reported as:
Mean · Seconds
Tear Film Break-up Time
SecondsTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Tear Film Break-up Time8.5 ± 6.17.7 ± 4.98.5 ± 5.7
SecondaryCorneal Staining Grade

Assessed by the investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5. The higher the grade the worse the staining.

Time frame:
following 3 days of treatment
Reported as:
Mean · Units on a scale
Corneal Staining Grade
Units on a scaleTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Corneal Staining Grade1.2 ± 0.91.1 ± 0.91.0 ± 0.8
SecondaryCorneal Staining Count

Assessed by the investigator using a slit lamp, counting the number of spots.

Time frame:
following 3 days of treatment
Reported as:
Mean · Number of spots
Corneal Staining Count
Number of spotsTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Corneal Staining Count10.5 ± 12.510.4 ± 13.48.3 ± 8.3
SecondaryIntraoclular Pressure
Time frame:
following 3 days of treatment
Reported as:
Mean · mm of mercury
Intraoclular Pressure
mm of mercuryTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Intraoclular Pressure16.3 ± 3.116.2 ± 2.416.2 ± 2.2
SecondaryBasic Schirmer's

Schirmer's measures basic tear function. The higher the number, the less dry the eye.

Time frame:
following 3 days of treatment
Reported as:
Mean · mm of moisture
Basic Schirmer's
mm of moistureTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Basic Schirmer's17.7 ± 9.714.8 ± 7.315.4 ± 6.4
SecondaryConjunctival Staining - Nasal Grade

Assessed by investigator using a slit lamp and the Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.

Time frame:
following 3 days of treatment
Reported as:
Mean · Units on a scale
Conjunctival Staining - Nasal Grade
Units on a scaleTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Conjunctival Staining - Nasal Grade1.2 ± 0.91.1 ± 1.01.3 ± 1.0
SecondaryConjunctival Staining - Nasal Count

Assessed by investigator using slit lamp and counting number of spots.

Time frame:
following 3 days of treatment
Reported as:
Mean · number of spots
Conjunctival Staining - Nasal Count
number of spotsTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Conjunctival Staining - Nasal Count11.0 ± 12.510.3 ± 15.712.9 ± 14.8
SecondaryConjunctival Staining - Temporal Grade

Assessed by investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.

Time frame:
following 3 days of treatment
Reported as:
Mean · Units on a scale
Conjunctival Staining - Temporal Grade
Units on a scaleTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Conjunctival Staining - Temporal Grade0.8 ± 0.60.7 ± 0.70.8 ± 0.7
SecondaryConjunctival Staining - Temporal Count

Assessed by investigator using a slit lamp and counting number of spots.

Time frame:
following 3 days of treatment
Reported as:
Mean · number of spots
Conjunctival Staining - Temporal Count
number of spotsTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Conjunctival Staining - Temporal Count4.7 ± 7.34.8 ± 8.65.3 ± 6.7
SecondaryVisual Acuity

The visual acuity score is a count of the number of letters the subject successfully read from the eye chart. The higher the score, the better the vision.

Time frame:
following 3 days of treatment
Reported as:
Mean · number of letters
Visual Acuity
number of lettersTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
Visual Acuity52.3 ± 5.652.5 ± 6.151.4 ± 5.8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Timolol Hemihydrate 0.5%—0/30 (0%)2/30 (6.7%)
Timolol Maleate 0.5%—0/30 (0%)2/30 (6.7%)
Timolol Maleate Gel Forming Solution 0.5%—0/30 (0%)0/30 (0%)
Most frequent other events
Most frequent other events
EventTimolol Hemihydrate 0.5%Timolol Maleate 0.5%Timolol Maleate Gel Forming Solution 0.5%
TearingEye disorders2/300/300/30
Blurred VisionEye disorders0/302/300/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall
Mean66.3 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female15
Male15
Region of Enrollment
Region of Enrollment(participants)Overall
United States30
08

Study locations

2 sites
  • Bourbonnais, Illinois, United States
  • Charlotte, North Carolina, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2008
First posted
Dec 9, 2008
Start
Nov 2008
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Oct 20, 2010
Last update
Mar 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00804648
Lead sponsor
Vistakon Pharmaceuticals
Responsible party
Sponsor
First posted
Dec 9, 2008
Start date
Nov 2008
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Oct 20, 2010
Last update
Mar 6, 2015

Study contacts

William C. Stewart, MD
study director · PRN Pharmacuetical Research Network, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Timolol

Start the discussion